Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Equity Average (2022 - 2026)

Centessa Pharmaceuticals has reported Equity Average over the past 4 years, most recently at $414.2 million for Q4 2025.

  • Quarterly Equity Average fell 8.02% to $414.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $414.2 million through Dec 2025, down 8.02% year-over-year, with the annual reading at $464.2 million for FY2025, 45.57% up from the prior year.
  • Equity Average was $414.2 million for Q4 2025 at Centessa Pharmaceuticals, up from $323.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $485.9 million in Q1 2022 and troughed at $225.7 million in Q1 2024.
  • The 4-year median for Equity Average is $360.1 million (2022), against an average of $351.2 million.
  • Year-over-year, Equity Average crashed 36.69% in 2023 and then soared 81.72% in 2024.
  • A 4-year view of Equity Average shows it stood at $354.5 million in 2022, then plummeted by 30.1% to $247.8 million in 2023, then skyrocketed by 81.72% to $450.3 million in 2024, then fell by 8.02% to $414.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Equity Average are $414.2 million (Q4 2025), $323.2 million (Q3 2025), and $365.6 million (Q2 2025).